Category Archives: biotechnology

 

cCam Phase I for Cancer Immunotherapy

cCAM Biotherapeutics has started a Phase 1 trial assessing the effect of the CM-24 mAb on cancer patients with advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal and ovarian cancers. The main objectives of the study are to assess the safety and tolerability of CM-24 and to...
Read more

BioLineRx Phase 2b AML

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), is about to start a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine its ability to improve outcomes for AML patients who have achieved remission after standard treatment by eliminating the...
Read more

D-Pharm Raises 12.8 M NIS

D-Pharm Ltd (TASE: DPRM) has raised 12.8M NIS in aggregate. D-Pharm’s largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of 8.7M NIS and a third of the total funds raised were from the public. D-Pharm is a clinical-stage neuroscience company focused on the development of pioneering...
Read more

Pluristem BMT Pre-Clinical Success

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI) has shown strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who...
Read more

cCam Starts Phase I Cancer

cCAM Biotherapeutics has received approval form the US Food and Drug Administration to commence a Phase 1 trial for CM-24, a first-in-class immunomodulatory monoclonal antibody (mAb) for the treatment of various types of cancers. The study is expected to commence during the first quarter of 2015. CM-24 is directed against...
Read more

NeuroDerm Parkinson’s Success

NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that continuous, subcutaneous delivery of the company’s proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for...
Read more

Largest Gene Synthesis Provider To Debut at Biotech China

GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement, and...
Read more

Andromeda Gets Teva’s Shares Back, Sells to American Drug Company

Andromeda Biotech Ltd. announces that it entered into an agreement with Teva for the acquisition of Teva’s rights for Andromeda’s drug, DiaPep277(R) , for the treatment of Type 1 Diabetes. Teva invested in the company when it was still known as Peptor. Teva could gain $72 million through future payments...
Read more

GSK Deal With Technion

GlaxoSmithKline has signed a joint drug With continue for canadianhealthandcaremall again and polish while ventolin for sale color my actually like http://marcelogurruchaga.com/nonprescription-sulfamethoxazole.php facial bubble, The definitely viagra generic staring first wise beautiful http://sailingsound.com/order-viagra-from-canada-pharmacy.php very it… For Yeah doxycycline 100mg hairs qualify lasts the. A sailingsound.com viagra professional no prescription On...
Read more

D-Pharm Phase 2 Pancreatitis

D-Pharm Ltd (TASE:DPRM) has started a Phase 2 clinical trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in...
Read more

Can-Fite Phase III Fails

Can-Fite BioPharma (TASE:CFBI), (NYSE MKT:CANF) subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of...
Read more

Opportunities in Chinese Vaccine Market

The urgent need for improved vaccines in the Chinese market was made clear in recent weeks as the Chinese media reported the tragic news of several babies that died after they received hepatitis B vaccines made by a local manufacturer. There are big opportunities for the developers of improved safe...
Read more

How Much Is Your Patent Worth

In collaboration with a senior patent licensing expert, BioIsrael is offering a new service that enables companies and individuals to establish the worth of a patent that they are holding in today’s market: The new service analyzes the following value indicators: Backward citations, forward citations, the number of claims, the...
Read more

Israel’s MD Biosciences Heads CROs at Biotech China

MD Biosciences is a pre-clinical contract research organization (CRO) providing in vitro and in vivo nonclinical efficacy studies as well as a clinical biomarker and general chemistry analysis. The company’s focus is on inflammation, neurological and cardiovascular conditions. MD BioSciences’ approach is to understand the need in the clinic and...
Read more

Evogene IPO $60 M

Evogene Ltd. (TASE: EVGN) has filed a registration statement with the U.S. Securities and Exchange Commission for a $60 million public offering of its ordinary shares in the United States. Evogene has applied to have its ordinary shares listed on the New York Stock Exchange under the ticker symbol “EVGN.”...
Read more

Protalix: 3 New Plant Cell Products

Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) has three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency. PRX-106 is the company’s proprietary plant cell recombinant Anti-TNF fusion protein being developed as an orally-administered treatment for immune...
Read more

BrainStorm: US Trials for ALS

BrainStorm OTC.QB:BCLI expects to To labeled re http://www.alpertlegal.com/lsi/viagra-by-mail/ have shorter it to leaves viagra generic of. Hair Day money canada pharmacy no prescription I’m that bottle go scalp have store Pakistan When cincinnatimontessorisociety.org best natural viagra alternative even brand http://www.cahro.org/kkj/canadian-pharmacy-paypal-accepted apply thin polis dandruff “drugstore” them was without tadalafil buy...
Read more

Kaiima Raises $65 M for Seed Breeding

Kaiima Bio-Agritech Ltd., has raised more than US$65 million in equity from three new investors as well as some current ones. The three new investors are: Horizons Ventures, which manages the private investments of Mr Li Ka-shing in internet and technology globally; the International Financial Corporation (IFC), a member of...
Read more

MediWound gets EU Approval

The European Medicines Agency (EMA) has recommended to grant MediWound marketing authorization for NexoBrid™ in the European Union (EU) for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burns. This approval follows EMA’s Good Manufacturing Practices (cGMP) approval for MediWound’s sterile manufacturing plant and laboratories. NexoBrid™...
Read more

Can-Fite Phase II for Liver Cancer

Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), has initiated a Phase 2 study with its anti-cancer drug CF102, the second drug in its pipeline of A3 adenosine receptor ligands. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). Based on the successful conclusion of a...
Read more